Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Teknologi·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Teknologi·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% peluang
Polymarket

$11,314 Vol.

13% peluang
Polymarket

$11,314 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 feasibility agreement with Peptron grants only a non-exclusive, evaluation-stage license for internal R&D on the SmartDepot ultrasonic spray-dried PLGA microsphere platform, explicitly limiting use to technical assessment of sustained-release peptide formulations rather than any commercial rights. The deal, extended to a 24-month maximum ending October 7, 2026, allows termination on 30 days’ notice, and no binding technology-transfer or commercialization pact has been disclosed despite nearly two years of joint studies on GLP-1 candidates and recent expansion into CNS applications. With weeks remaining and only early preclinical data shared, trader consensus heavily favors “No” at 87.5% because the evaluation window has not yet produced the definitive commercial license required for resolution.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314
Tanggal Berakhir
Oct 7, 2026
Pasar Dibuka
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 feasibility agreement with Peptron grants only a non-exclusive, evaluation-stage license for internal R&D on the SmartDepot ultrasonic spray-dried PLGA microsphere platform, explicitly limiting use to technical assessment of sustained-release peptide formulations rather than any commercial rights. The deal, extended to a 24-month maximum ending October 7, 2026, allows termination on 30 days’ notice, and no binding technology-transfer or commercialization pact has been disclosed despite nearly two years of joint studies on GLP-1 candidates and recent expansion into CNS applications. With weeks remaining and only early preclinical data shared, trader consensus heavily favors “No” at 87.5% because the evaluation window has not yet produced the definitive commercial license required for resolution.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314
Tanggal Berakhir
Oct 7, 2026
Pasar Dibuka
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Terkait

icon for Skin cancer vaccine BLA submitted by June 30, 2027?

Skin cancer vaccine BLA submitted by June 30, 2027?

88%
icon for Apakah FDA menyetujui Retatrutide tahun ini?

Apakah FDA menyetujui Retatrutide tahun ini?

3%
Ya
icon for Skin cancer vaccine FDA approved by December 31, 2027?

Skin cancer vaccine FDA approved by December 31, 2027?

68%

Hati-hati dengan link eksternal.

Pertanyaan yang Sering Diajukan

"Eli Lilly licenses Peptron’s SmartDepot by October 7?" adalah pasar prediksi di Polymarket di mana trader membeli dan menjual saham "Ya" atau "Tidak" berdasarkan apakah mereka yakin event ini akan terjadi. Probabilitas crowd-sourced saat ini adalah 13% untuk "Yes." Misalnya, jika "Ya" dihargai 13¢, pasar secara kolektif memberikan peluang 13% bahwa event ini akan terjadi. Peluang ini bergeser terus-menerus saat trader bereaksi terhadap perkembangan dan informasi baru. Saham dengan hasil yang benar bisa ditukarkan seharga $1 setiap saham saat pasar diselesaikan.

Per hari ini, "Eli Lilly licenses Peptron’s SmartDepot by October 7?" telah menghasilkan $11.3K dalam total volume trading sejak pasar diluncurkan pada May 5, 2026. Tingkat aktivitas trading ini mencerminkan keterlibatan kuat dari komunitas Polymarket dan membantu memastikan bahwa peluang saat ini diinformasikan oleh kumpulan besar peserta pasar. Kamu bisa melacak pergerakan harga langsung dan trading di hasil apa pun langsung di halaman ini.

Untuk trading di "Eli Lilly licenses Peptron’s SmartDepot by October 7?," cukup pilih apakah kamu yakin jawabannya "Ya" atau "Tidak." Setiap sisi memiliki harga saat ini yang mencerminkan probabilitas tersirat pasar. Masukkan jumlah kamu dan klik "Trade." Jika kamu membeli saham "Ya" dan hasilnya diselesaikan sebagai "Ya," setiap saham membayar $1. Jika diselesaikan sebagai "Tidak," saham "Ya" kamu bernilai $0. Kamu juga bisa menjual sahammu kapan saja sebelum resolusi jika kamu ingin mengamankan keuntungan atau memotong kerugian.

Probabilitas saat ini untuk "Eli Lilly licenses Peptron’s SmartDepot by October 7?" adalah 13% untuk "Yes." Ini berarti keramaian Polymarket saat ini percaya ada peluang 13% bahwa event ini akan terjadi. Peluang ini diperbarui secara real-time berdasarkan trade aktual, memberikan sinyal yang terus diperbarui tentang apa yang diharapkan pasar.

Aturan resolusi untuk "Eli Lilly licenses Peptron’s SmartDepot by October 7?" mendefinisikan dengan tepat apa yang harus terjadi agar setiap hasil dinyatakan sebagai pemenang — termasuk sumber data resmi yang digunakan untuk menentukan hasilnya. Kamu bisa meninjau kriteria resolusi lengkap di bagian "Aturan" di halaman ini di atas komentar. Kami menyarankan membaca aturan dengan cermat sebelum trading, karena mereka menentukan kondisi tepat, kasus khusus, dan sumber yang mengatur bagaimana pasar ini diselesaikan.